Orforglipron: Lilly's Oral GLP-1 Pill, Cost, and Launch Timeline

Medically reviewed by a licensed healthcare professional. Last updated May 2026.

Key Takeaways

• Foundayo (orforglipron) is Lilly's once-daily oral GLP-1, FDA-approved on April 1, 2026 for chronic weight management.
• ATTAIN-1 phase 3 trial showed 12.4% mean body weight reduction among completers (11.1% regardless of completion) at the 36 mg trial high dose over 72 weeks.
• Non-peptide small molecule. No injection, no peptide-synthesis bottleneck, no Rybelsus-style empty-stomach restrictions.
• Pricing: $649/mo list, LillyDirect self-pay $149-$349/mo by dose, $25/mo with the Lilly Savings Card for eligible commercial insurance.
• Dose ladder: 0.8 mg → 2.5 mg → 5.5 mg → 9 mg → 14.5 mg → 17.2 mg, titrated monthly.
• Most patients on a working injectable shouldn't switch. The case for Foundayo is strongest for injection refusers and Rybelsus / Wegovy pill non-responders.

If you've been on the GLP-1 internet for any length of time, you've probably seen orforglipron mentioned. Lilly sat on a once-daily oral GLP-1 in their pipeline for years, filed the FDA application in late 2025, and the FDA approved it on April 1, 2026 under the brand name Foundayo. LillyDirect started shipping five days later. The questions I keep getting from patients are some version of: "Should I switch to the pill?" and "What does it actually cost?"

This is the answer to both.

What orforglipron actually is

Most of the GLP-1 drugs you've heard of (semaglutide, tirzepatide, liraglutide, dulaglutide) are peptides. They're chains of amino acids that mimic the gut hormone GLP-1, and they have to be injected or, in the case of Rybelsus, taken with elaborate absorption tricks (empty stomach, sip of water, no food for 30 minutes) to survive the digestive system.

Orforglipron is different at the molecular level. It's a non-peptide small molecule that activates the same GLP-1 receptor through completely different chemistry. The practical consequence is that it can be formulated as a regular oral pill, taken any time of day, with or without food. No injection. No peptide-synthesis manufacturing capacity. No empty-stomach window.

This matters for three groups:

1. Patients who refuse injections. A meaningful share of the obesity population won't start injectable GLP-1s under any circumstances. Orforglipron is the first option that fits them.
2. Anyone in a market with shortage issues. Peptide-synthesis capacity has been the bottleneck for tirzepatide and semaglutide. Small-molecule manufacturing is much more elastic.
3. Patients who tried Rybelsus and bounced. The Rybelsus empty-stomach protocol is a real adherence problem. Orforglipron won't have it.

What the trial data actually shows

The headline number from the ATTAIN-1 phase 3 trial: 12.4% mean body weight reduction among completers (11.1% regardless of completion) at the 36 mg trial high dose over 72 weeks in adults with obesity. The lower doses showed proportionally smaller effects.

For context, here's how that stacks up:

The ACHIEVE program tested orforglipron in type 2 diabetes and showed HbA1c improvements comparable to injectable GLP-1s like Ozempic. It's not as strong as injectable tirzepatide (Mounjaro), but it's a real option for diabetes patients who won't inject.

The side-effect profile in the trials was the GLP-1-class profile we already know: nausea, diarrhea, and constipation as the dominant complaints, mostly during titration. No surprise safety signals that would derail FDA review.

What it costs

Lilly published pricing at launch:

• List price: $649/month, regardless of dose strength.
• LillyDirect self-pay: $149/month for the 0.8 mg starter dose, scaling to $349/month for the 17.2 mg high dose. Available cash-pay through LillyDirect Pharmacy with no insurance required.
• Lilly Savings Card: Eligible commercial-insurance patients pay as low as $25/month. Medicare, Medicaid, and other government programs are excluded.
• Insurance coverage: Variable. Most commercial plans require prior authorization with documented BMI ≥30 (or ≥27 with comorbidities). Medicare Part D coverage will follow the GLP-1 Bridge program rules starting July 1, 2026.

The LillyDirect self-pay tiers undercut Wegovy pill ($199-$349/month at NovoCare) at the entry dose and roughly match it at the high dose. They also undercut compounded oral GLP-1 in some markets, though compounded products remain cheaper at $99-$199/month from many telehealth providers.

The dose ladder

Foundayo is titrated monthly through six dose strengths: 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg, taken once daily. Most patients escalate every four weeks based on tolerance, with maintenance at the highest tolerated dose. Unlike Rybelsus, no food, water, or empty-stomach window is required.

Where to get it

LillyDirect started shipping Foundayo on April 6, 2026. Retail pharmacy availability followed within weeks. Currently the easiest paths:

• LillyDirect.com — direct from Lilly. Self-pay, no insurance required. Fastest start.
• Retail pharmacy with insurance — CVS, Walgreens, Walmart, Costco. Prior authorization typically required.
• Telehealth GLP-1 providers — many of the major telehealth providers prescribe Foundayo. Take our quiz to find one that matches your insurance and budget.

Should you switch?

For most patients on a working injectable (Zepbound, Wegovy, Mounjaro): no, don't switch.

The math doesn't favor it:

• Zepbound 15 mg still produces ~21% mean weight loss vs Foundayo's 12.4% among completers (11.1% overall) at the 36 mg trial high dose.
• Wegovy HD 7.2 mg sits at ~20.7%.
• LillyDirect already offers Zepbound at $299 to $449 self-pay, comparable to Foundayo's $149-$349.
• Switching mid-treatment resets your titration progress.

For specific cases where Foundayo makes sense:

• You have a hard injection refusal. Foundayo is the first FDA-approved oral GLP-1 specifically for weight management, and it doesn't carry Rybelsus's food restrictions.
• You're stable on Wegovy pill 25 mg or Rybelsus and getting limited results. Switching to Foundayo may produce better outcomes given the higher trial efficacy.
• You're in a market where injectable supply is unreliable. Small-molecule manufacturing is more elastic than peptide synthesis, so Foundayo is less prone to shortage.
• Self-pay on LillyDirect for Foundayo beats what you're paying for an injectable today. Run the actual numbers; Zepbound LillyDirect can be competitive.

For the patient population that can take an injectable GLP-1 and is getting results: stay on what's working. We covered the broader switching question in our GLP-1 microdosing guide and our stopping GLP-1s post.

What this means for the GLP-1 market

• Wegovy pill (Novo Nordisk's oral semaglutide for weight loss) is squeezed. Foundayo outperforms it on weight loss and has no empty-stomach restriction.
• Rybelsus (oral semaglutide for diabetes) is harder to justify. Same mechanism class, harder dosing protocol, lower efficacy.
• Zepbound and Wegovy injectable stay dominant for the maximum-effect patient. Most people who want 20%+ weight loss will continue with injectables.
• The overall GLP-1 market grows. Patients who refused injections are entering the market for the first time. That expansion is the bigger story than any share-shift between existing brands.

Foundayo isn't replacing what most patients are already taking. It's expanding who's taking something. That's the commercially important story.

Bottom line

If you're already on a GLP-1 and it's working, stay on it. Don't switch to chase the pill format unless you have a specific reason — injection refusal, Rybelsus underperformance, or a self-pay arbitrage that pencils out.

If you've been holding out for an oral option, Foundayo is now available. Take our provider-matching quiz to find a clinic or telehealth provider that prescribes it, or read the Wegovy pill vs injection comparison if you're choosing between the two oral options.

Sources

1. Eli Lilly Q4 2025 earnings call: orforglipron NDA filing
2. ATTAIN-1 trial results, Lilly press release 2025
3. ACHIEVE-1 trial in type 2 diabetes, Lilly press release 2025
4. Orforglipron mechanism overview, Nature Medicine 2024
5. Wegovy pill (oral semaglutide 25 mg) trial results, NEJM 2024
6. SURMOUNT-1 trial results, NEJM 2022